LAUSANNE, Switzerland, May 24, 2007 - Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, announces the successful completion of the European Mutual Recognition Procedure (MRP) for Salvacyl(r)/Moapar(r) 3-month sustained release formulation, in Germany, Belgium, Denmark, Finland, France, Norway, the Netherlands and the United Kingdom. Last year, Salvacyl(r)/Moapar(r) was approved in Sweden, which was the reference member state for the MRP. Debiopharm is seeking a commercial partner for the sales and marketing of this product.
